Our investment in UCB
UCB focuses on discovering and developing innovative treatments to transform the lives of patients suffering from serious illnesses that affect their immune system or their central nervous system.
The ambition of UCB is to give those suffering from serious illnesses the freedom to live their lives as well as possible, protected from the uncertainties caused by diseases. All the staff at UCB aim to work on a sustainable basis for their company, their colleagues, the communities around them and the planet.
Key figures of the UCB group (listed on Euronext Brussels)
6.15
€ b turnover
(2023 : € 5.25 b)
29%
R&D / turnover ratio
(2023 : 31%)
9
Molecules in clinical pipeline
(2023 : 10)
9,378
UCB staff members worldwide
(2023 : 9,083)
24%
Adjusted EBITDA / turnover ratio
(2023 : 25.7%)
3.1
m patients have access to the solutions provided by UCB
-33%
Reduction in CO21 emissions
(2023 : -55%)
ESG ratings2
Sustainalytics : 13,7
MSCI : AA
ISS : B-
1This excludes emissions from Scope 3 Category 1, compared to our 2019 baseline in absolute numbers
2Ratings on UCB annual report publication date
